GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress -Recent Successful $101 Million Financing Accelerates Epidiolex® Development in Childhood Epilepsy- -Conference Call Today at 8:00 a.m. ET, 1:00 p.m. GMT- LONDON, Feb. 5, 2014 (GLOBE...

GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014 LONDON, Jan. 29, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing...

GW Pharmaceuticals plc Announces the Closing of Its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs LONDON, Jan. 14, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing...

Ipsen and GW Pharmaceuticals plc Enter Into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America The intended indication for Sativex® is the treatment of spasticity due to multiple sclerosis Sativex® a companion drug to Dysport® in neurology LONDON and PARIS, Jan. 14,...